Brief: Silence Therapeutics Announces Preliminary Single Dose Results From SLN124 Phase 1 Study In Patients With Thalassemia

Silence Therapeutics

29/09/2022 12:03

Sept 29 (Reuters) - Silence Therapeutics PLC  SLNCF.PK :
    * SILENCE THERAPEUTICS ANNOUNCES PRELIMINARY SINGLE DOSE
RESULTS
FROM SLN124 PHASE 1 STUDY IN PATIENTS WITH THALASSEMIA

Source text for Eikon:  ID:nBw44Mz1ta 
Further company coverage:  SLNCF.PK 
 ((Reuters.Briefs@thomsonreuters.com;;))